Immunovant, Inc.
Close on Oct 19, 2026
- Market cap
- $5.68B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2027 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | – | $-0.75 | – |
| Q4 FY2026 Ended Mar 31, 2026 | May 20, 2026 | Before market open | – | – | – |
| Q3 FY2026 Ended Dec 31, 2025 | Feb 6, 2026 | Before market open | – | $-0.61 | – |
| Q2 FY2026 Ended Sep 30, 2025 | Nov 10, 2025 | Before market open | – | $-0.73 | – |
| Q1 FY2026 Ended Jun 30, 2025 | Aug 11, 2025 | Before market open | – | – | – |
| Q4 FY2025 Ended Mar 31, 2025 | May 29, 2025 | Before market open | – | $-0.64 | – |
| Q3 FY2025 Ended Dec 31, 2024 | Feb 6, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | $-0.74 | – |
| Q1 FY2025 Ended Jun 30, 2024 | Aug 6, 2024 | After market close | – | $-0.60 | – |
| Q4 FY2024 Ended Mar 31, 2024 | May 29, 2024 | After market close | – | $-0.52 | – |
| Q3 FY2024 Ended Dec 31, 2023 | Feb 12, 2024 | Before market open | – | $-0.36 | – |
Press releases
Announcements Immunovant filed with the SEC
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
Results of operations · EX-99.1 to Form 8-K
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
Results of operations · EX-99.1 to Form 8-K
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
Results of operations · EX-99.1 to Form 8-K
Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025
Results of operations · EX-99.1 to Form 8-K
Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Targeted science, Tailored solutions for people with autoimmune disease Batoclimab Graves’ Disease Proof-of-Concept Study Remission Data September 2025 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025
Results of operations · EX-99.1 to Form 8-K
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
Results of operations · EX-99.1 to Form 8-K
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Immunovant Corporate Update April 21, 2025 Exhibit 99.2
Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Targeted science, Tailored solutions for people with autoimmune disease MG & CIDP Results March 2025 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Immunovant Reports Financial Results for the Quarter Ended December 31, 2024
Results of operations · EX-99.1 to Form 8-K
Targeted science, Tailored solutions for people with autoimmune disease 2025 J.P. Morgan Healthcare Conference January 14, 2025 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Immunovant Announces $450 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
Results of operations · Other events · EX-99.1 to Form 8-K
Immunovant Development Update November 7, 2024 Exhibit 99.2
Results of operations · Other events · EX-99.2 to Form 8-K
Immunovant Provides Update on Graves’ Disease Development Program
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Targeted science, Tailored solutions for people with autoimmune disease Graves’ Disease Program Update September 9, 2024 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024
Results of operations · EX-99.1 to Form 8-K
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024
Results of operations · EX-99.1 to Form 8-K
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
Results of operations · EX-99.1 to Form 8-K
Targeted science, Tailored solutions for people with autoimmune disease 42nd Annual J.P. Morgan Healthcare Conference January 9, 2024 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Targeted science, Tailored solutions for people with autoimmune disease Portfolio Update November 28, 2023 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023
Results of operations · EX-99.1 to Form 8-K
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Targeted science, Tailored solutions for people with autoimmune disease IMVT-1402 Initial First-in-human Data Presentation September 26, 2023 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023
Results of operations · EX-99.1 to Form 8-K
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023
Results of operations · Other events · EX-99.1 to Form 8-K
IMVT-1402 Update May 22, 2023 Exhibit 99.2
Results of operations · Other events · EX-99.2 to Form 8-K
Targeted Science, Tailored Solutions Corporate Presentation March 2023 Exhibit 99.1
Other events · EX-99.1 to Form 8-K
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022
Results of operations · EX-99.1 to Form 8-K
Corporate Presentation January 2023 Exhibit 99.1
Other events · EX-99.1 to Form 8-K
LifeSci Capital Fireside Chat December 8, 2022 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022
Results of operations · EX-99.1 to Form 8-K
Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CONFIDENTIAL Building a Leading Franchise Next Generation FcRn: IMVT-1402 September 2022 For Investor Audiences Only Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K